Ultrasound-guided Thermal Ablation for Papillary Thyroid Carcinoma

NCT06733740 | Recruiting

• 1 other identifier: 2024-655
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate long-term outcomes of ultrasound-guided thermal ablation for the treatment of papillary thyroid carcinoma

Conditions

Papillary Thyroid Cancer

Outcome Measures

Primary Outcomes (1)

• rate of disease progression

  cervical lymph node metastases, recurrent tumors and persistent tumors confirmed by pathology

  through study completion, an average of 6 months

Secondary Outcomes (5)

• Rate of complications

  1 week

• Rate of tumor disappearance

  through study completion, an average of 6 months

• Rate of volume reduction

  through study completion, an average of 6 months

• rate of change of thyroid function

  through study completion, an average of 6 months

• rate of delayed surgery

  through study completion, an average of 1 year

Interventions

ultrasound-guided thermal ablation PROCEDURE

ultrasound-guided thermal ablation to treat tumor

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

patients with papillary thyroid carcinoma who refuse surgery or active surveillance and choose thermal ablation

You may qualify if:

• patients age between 18 and 80 year old, both sex
• papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration
• the largest diameter ≤2.0 cm
• no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, neck and chest CT
• follow-up period ≥12 months

You may not qualify if:

• patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy
• history of neck radiation
• coagulation disorder, serious heart, respiratory, liver, or renal failure
• dysfunction of the vocal cord on the opposite side

Sponsors & Collaborators

• Chinese PLA General Hospital: lead

Study Sites (1)

Chinese PLA General Hospital

Beijing, Beijing Municipality, 100853, China

RECRUITING

MeSH Terms

Conditions

Thyroid Cancer, Papillary

Interventions

Transurethral Resection of Prostate

Condition Hierarchy (Ancestors)

Adenocarcinoma, Papillary; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Thyroid Neoplasms; Endocrine Gland Neoplasms; Neoplasms by Site; Head and Neck Neoplasms; Endocrine System Diseases; Thyroid Diseases

Intervention Hierarchy (Ancestors)

Prostatectomy; Urologic Surgical Procedures, Male; Urologic Surgical Procedures; Urogenital Surgical Procedures; Surgical Procedures, Operative

Study Officials

• Yukun Luo

  Chinese PLA General Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Lin Yan, MD

CONTACT

13811237313 ext 86; gemma-y@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Professor

Study Record Dates

• First Submitted: December 6, 2024
• First Posted: December 13, 2024
• Study Start: December 10, 2024
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2030
• Last Updated: February 14, 2025

Record last verified: 2025-02

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)